Patents by Inventor Shyama Sidique

Shyama Sidique has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROCYCLIC COMPOUNDS
    Publication number: 20170008888
    Abstract: Provided herein are compounds of formula I and compositions containing the compounds. The compounds and compositions are useful in the methods of inhibiting the action of ERK5, a BET family protein or both. In certain embodiments, the compounds and compositions are useful in the prevention, amelioration or treatment of a ERK5-mediated disease, a BET protein-mediated disease or both.
    Type: Application
    Filed: February 26, 2015
    Publication date: January 12, 2017
    Inventors: Yi Hu, Emme C. K. Lin, Bei Li, Shyama Sidique, Jonathan S. Rosenblum, Oana M. Cociorva, Kevin R. Shreder, Shigeki Seto
  • Positive allosteric modulators of group II mGluRs
    Patent number: 8748632
    Abstract: The disclosure provides compounds and compositions, and methods of using these compounds and compositions, as positive allosteric modulators of the metabotropic glutamate subtype 2 (mGlu2) receptor, and for treating CNS disorders associated with the mGlu2 receptor including schizophrenia, anxiety, addiction, e.g. cocaine addiction, nicotine addiction, and the like.
    Type: Grant
    Filed: March 18, 2011
    Date of Patent: June 10, 2014
    Assignees: Sanford-Burnham Medical Research Institute, The Regents of the University of California
    Inventors: Nicholas D. P. Cosford, Dhanya Raveendra Panickar, Shyama Sidique, Svetlana Semenova, Athinia Markou
  • POSITIVE ALLOSTERIC MODULATORS OF GROUP II MGLURS
    Publication number: 20120071503
    Abstract: The disclosure provides compounds and compositions, and methods of using these compounds and compositions, as positive allosteric modulators of the metabotropic glutamate subtype 2 (mGlu2) receptor, and for treating CNS disorders associated with the mGlu2 receptor including schizophrenia, anxiety, addiction, e.g. cocaine addiction, nicotine addiction, and the like.
    Type: Application
    Filed: March 18, 2011
    Publication date: March 22, 2012
    Applicant: Sanford-Burnham Medical Research Institute
    Inventors: Nicholas D. P. Cosford, Dhanya Raveendra Panickar, Shyama Sidique